Safety and Efficacy of Liposomal Cytarabine/Daunorubicin (CPX-351) in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia

被引：1
|
作者：
Przespolewski, Amanda [1 ]
Talati, Chetasi [2 ]
Vachhani, Pankit [3 ]
Sanikommu, Srinivasa Reddy [4 ]
Thota, Swapna [1 ]
Baron, Jeffrey [1 ]
Griffiths, Elizabeth A. [1 ]
Thompson, James E. [1 ]
Sweet, Kendra L. [5 ]
Wang, Eunice S. [1 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Div Malignant Hematol, Tampa, FL USA
[3] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[4] Carolinas Healthcare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-113002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2677
引用
收藏
页数：3
相关论文
共 50 条
  • [21] IN VIVO RAT METABOLISM OF AN ACUTE MYELOID LEUKEMIA (AML) DRUG CPX-351 (CYTARABINE: DAUNORUBICIN) LIPOSOME INJECTION
    Kim-Kang, Heasook
    Yi, Yijun
    Wang, Peter L.
    Tardi, Paul
    Xie, Sherwin
    Mayer, Lawrence
    DRUG METABOLISM REVIEWS, 2015, 47 : 187 - 187
  • [22] CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia
    Talati, Chetasi
    Lancet, Jeffrey E.
    FUTURE ONCOLOGY, 2018, 14 (12) : 1147 - 1154
  • [23] Evaluation of CPX-351 (cytarabine:daunorubicin) liposome injection efficacy in acute lymphoblastic leukemia (ALL) xenograft models
    Mayer, Lawrence
    Carol, Hernan
    Morton, Christopher L.
    Harasym, Troy
    Smith, Malcolm A.
    Lock, Richard B.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [24] CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia
    Lee, Dasom
    Jain, Akriti G.
    Deutsch, Yehuda
    Eatrides, Jennifer
    Chan, Onyee
    Padron, Eric
    Kuykendall, Andrew
    Komrokji, Rami
    Lancet, Jeffrey
    Sallman, David
    Talati, Chetasi
    Sweet, Kendra
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (10): : 774 - 779
  • [25] CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?
    Brunetti, Claudia
    Anelli, Luisa
    Zagaria, Antonella
    Specchia, Giorgina
    Albano, Francesco
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (10) : 853 - 862
  • [26] PHARMACOLOGY OF CPX-351: A NANO-SCALE LIPOSOMAL FIXED MOLAR RATIO CYTARABINE-DAUNORUBICIN FOR PATIENTS WITH ADVANCED LEUKEMIA
    Feldman, E. J.
    Lancet, J. E.
    Kolitz, J. E.
    Trang, J. M.
    Mayer, I.
    Louie, A. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 67 - 67
  • [27] Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
    Feldman, E. J.
    Kolitz, J. E.
    Trang, J. M.
    Liboiron, B. D.
    Swenson, C. E.
    Chiarella, M. T.
    Mayer, L. D.
    Louie, A. C.
    Lancet, J. E.
    LEUKEMIA RESEARCH, 2012, 36 (10) : 1283 - 1289
  • [28] Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
    Medeiros, Bruno C.
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    Newell, Laura F.
    Lin, Tara L.
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen A.
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Daniel H.
    Hoering, Antje
    Chiarella, Michael T.
    Louie, Arthur C.
    Uy, Geoffrey L.
    BLOOD, 2016, 128 (22)
  • [29] CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML)
    Lancet, J. E.
    Cortes, J. E.
    Kovacsovics, T.
    Hogge, D.
    Kolitz, J. E.
    Tallman, M. S.
    Chiarella, M.
    Louie, A. C.
    Feldman, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Phase II trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with acute myeloid leukemia >60 years of age who have not been treated with intensive chemotherapy.
    Ritchie, Ellen K.
    Lee, Sangmin
    Desai, Pinkal M.
    Ball, Jeff
    Samuel, Michael S.
    Curcio, Tania
    Miah, Sumaiya
    Roboz, Gail J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345